Intellia Therapeutics Corporate Overview 2023 - Genome Editing

Intellia Therapeutics is a genome editing company leveraging CRISPR/Cas9 technology to develop treatments for serious diseases including ATTR amyloidosis, hereditary angioedema, and alpha-1 antitrypsin deficiency. The company maintains an in vivo and ex vivo clinical pipeline supported by collaborations with partners including Regeneron, Novartis, and others.